🇺🇸 FDA
Patent

US 8450321

6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor

granted A61PA61P1/00A61P1/04

Quick answer

US patent 8450321 (6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor) held by GILEAD CONNECTICUT, INC. expires Mon May 23 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
GILEAD CONNECTICUT, INC.
Grant date
Tue May 28 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 23 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
2
CPC classes
A61P, A61P1/00, A61P1/04, A61P11/00, A61P11/02